These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 34048176)

  • 21. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
    Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
    [No Abstract]   [Full Text] [Related]  

  • 24. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
    Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
    J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
    Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
    Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline variants screening of MLH1, MSH2, MSH6 and PMS2 genes in 64 Algerian Lynch syndrome families: The first nationwide study.
    Boumehdi AL; Cherbal F; Khider F; Oukkal M; Mahfouf H; Zebboudj F; Maaoui M
    Ann Hum Genet; 2022 Nov; 86(6):328-352. PubMed ID: 36073783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
    Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
    Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
    Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
    Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.
    Adar T; Rodgers LH; Shannon KM; Yoshida M; Ma T; Mattia A; Lauwers GY; Iafrate AJ; Hartford NM; Oliva E; Chung DC
    Cancer; 2018 Aug; 124(15):3145-3153. PubMed ID: 29750335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
    Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
    Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
    Hampel H; Pearlman R; de la Chapelle A; Pritchard CC; Zhao W; Jones D; Yilmaz A; Chen W; Frankel WL; Suarez AA; Cosgrove C; Backes F; Copeland L; Fowler J; O'Malley D; Salani R; McElroy JP; Stanich PP; Goodfellow P; Cohn DE
    Gynecol Oncol; 2021 Jan; 160(1):161-168. PubMed ID: 33393477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.